Year: 2015
Type: review
Abstract: Although integrity of the p53 signaling pathway in a given tumor was expected to be a critical determinant of response to therapies, most clinical studies failed to link p53 status and treatment outcome. Here, we present two opposite situations: one in which p53 is an essential effector of cure by targeted leukemia therapies and another one in advanced breast cancers in which p53 inactivation is required for the clinical efficacy of dose-dense chemotherapy. If p53 promotes or blocks therapy response, therapies must be tailored on its status in individual tumors.
Institutions: Centre National de la Recherche Scientifique, Inserm, Génomes, biologie cellulaire et thérapeutiques, Sorbonne Paris Cité, La Ligue Contre le Cancer, Hôpital Saint-Louis, Université Paris Diderot, Institut Universitaire d'Hématologie, Assistance Publique – Hôpitaux de Paris, Collège de France
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Award: Institut Saint-Louis
OpenAlex ID: W2184712565
